Catalyst pharmaceuticals, inc. (CPRX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
Operating Activities:
Net income (loss)

42,945

31,875

9,446

-12,023

-28,948

-34,003

-24,891

-21,230

-19,145

-18,412

-17,187

-16,964

-17,653

-18,072

-19,724

-20,219

-20,208

-20,232

-17,907

-18,468

-17,108

-15,509

-13,373

-14,275

-14,221

-12,154

-10,876

-7,585

-4,731

-4,076

0

0

0

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation

54

54

39

41

43

37

32

35

40

45

50

47

43

43

37

39

39

34

36

32

29

26

24

22

22

22

19

16

13

10

0

0

0

Amortization of right-of-use asset

246

243

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

4,410

3,824

3,705

3,646

3,512

3,550

3,006

2,778

2,625

2,407

2,411

2,413

2,132

1,836

1,923

1,722

1,728

1,585

1,296

1,410

1,069

777

532

134

157

175

337

336

336

340

0

0

0

Change in accrued interest and accretion of discount on investments

155

290

0

0

0

-

-

-

-

186

79

186

244

-886

-1,168

-1,797

-1,978

-65

-147

1,281

1,838

993

135

1,905

2,180

1,890

2,380

-1,636

-1,358

-1,129

0

0

0

(Increase) decrease in:
Accounts receivable, net

-332

10,536

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventory

2,114

1,900

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets and deposits

4,181

2,701

2,522

811

888

476

306

55

62

125

199

-29

-94

-456

-1,083

-210

91

452

576

3,519

3,549

2,943

3,328

-272

-359

299

877

947

1,000

1,110

0

0

0

Increase (decrease) in:
Accounts payable

-1,592

1,780

2,806

2,406

2,135

391

259

230

-112

1,012

26

-14

-333

-860

238

-609

200

-20

292

78

118

963

-948

789

364

-514

1,117

225

216

1,101

0

0

0

Accrued expenses and other liabilities

10,177

12,540

11,436

8,419

3,914

4,850

478

991

920

1,142

695

-467

-439

-480

-572

405

158

1,134

-357

3,612

3,290

2,748

3,865

-72

1,085

1,005

1,138

733

-113

-276

0

0

0

Operating lease liability

282

276

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) operating activities

49,840

34,611

13,968

-9,247

-28,082

-26,147

-21,825

-17,505

-15,945

-13,742

-14,124

-14,769

-15,912

-17,963

-18,183

-20,248

-20,150

-18,015

-17,363

-15,573

-14,311

-12,941

-13,092

-11,223

-10,051

-9,875

-7,339

-6,756

-6,088

-5,140

0

0

0

Investing Activities:
Purchases of property and equipment

-

19

76

99

97

92

0

0

0

-

-

-

-

-

-

-

-

23

37

36

47

57

43

30

17

9

54

54

56

52

0

0

0

Purchases of investments

-

34,725

34,725

29,772

14,888

36,790

36,730

36,759

31,818

3

39

10

36

68

43

71

11

-18

26

-32

9,998

8,979

15,790

20,015

8,992

9,978

0

0

0

-

-

-

-

Proceeds from maturities and sales of investments

56,569

71,969

0

0

0

-

-

-

0

-

-

-

-

3,717

3,148

948

-1

-1

-2

-2

-2

296

295

5,283

4,287

2,491

0

0

0

-

-

-

-

Net cash provided by (used in) investing activities

31,775

37,224

19,708

22,238

27,214

-15,082

-29,165

-36,771

-31,818

-3

521

2,750

3,584

3,552

3,016

773

-28

-6

-65

-6

-10,049

-8,741

-15,538

-19,751

-7,717

-7,496

-14,743

-10,545

-12,569

-14,059

0

0

0

Financing Activities:
Proceeds from issuance of common stock, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

34,873

0

0

0

-

-

-

-

-

-

-

9,564

9,564

0

0

0

Payment of employee withholding tax related to stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

11

0

0

0

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

Proceeds from issuance of preferred stock, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

Proceeds from issuance of convertible promissory note

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Proceeds from exercise of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,895

3,195

2,604

2,491

1,316

0

0

0

-

-

-

0

-

-

-

-

Proceeds from exercise of stock options

1,053

1,116

689

537

353

297

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

23

0

0

0

-

-

-

-

Net cash provided by (used in) financing activities

1,053

1,116

689

537

349

293

0

0

0

-

-

-

-

68

54

970

1,083

37,159

38,916

37,999

64,612

28,563

26,931

44,896

18,194

18,178

23,071

10,666

14,580

14,580

0

0

0

Net increase (decrease) in cash and cash equivalents

82,669

72,952

34,366

13,529

-518

-40,937

3,287

1,304

9,619

43,603

-10,309

-10,133

-12,246

-14,341

-15,112

-18,504

-19,095

19,138

21,486

22,419

40,250

6,880

-1,699

13,922

426

806

989

-6,635

-4,076

-4,619

0

0

0

Non-cash investing and financing activities:
Unrealized gain (loss) on available-for-sale securities

90

29

65

58

15

-20

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Exercise of liability classified warrants for common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,721

1,721

662

410

18

0

0

0

-

-

-

0

-

-

-

0

Non-cash incentive received from lessor

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

Conversion of note to common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0